Thomas Bachmann Appointed President of Bruker BioSpin Group
News Aug 19, 2013
The Bruker BioSpin Group is the global market and technology leader in analytical and preclinical magnetic resonance instrumentation, with major operations in Germany,Switzerland, France and the United States, as well as numerous applications and customer service centers around the world. The Bruker BioSpin Group operates in two divisions:
• Magnetic Resonance Spectroscopy (MRS) division, consisting of the three business units nuclear magnetic resonance (NMR), electron paramagnetic resonance (EPR) and compact magnetic resonance (CMR)
• Preclinical Imaging (PCI) division, consisting of the preclinical imaging product lines magnetic resonance imaging (MRI), magnetic particle imaging (MPI), X-ray micro-CT, as well as optical and PET/SPECT/CT molecular imaging.
Frank Laukien, Bruker's President and Chief Executive Officer, stated: "I am very pleased to welcome Thomas Bachmann to Bruker. His life-science background and his broad management experience will allow him to lead our excellent BioSpin management team in order to further accelerate our innovation, profitable growth and operational excellence initiatives. Thomas will be a valuable addition for all of Bruker due to his diversified industrial experience, his global customer and operations exposure, and his successful track record."
"Bruker is a premier brand in our analytical, life-science and diagnostic instruments industry, and an exceptional company that I have come to know well over the past few years," saidThomas Bachmann. "I am delighted to join Bruker, and together with an experienced management team I look forward to further developing the Bruker BioSpin Group. With emphasis on innovation for customers, applications development and market expansion, paired with operational excellence and margin expansion, Bruker BioSpin has significant value creation potential over the years to come."
Thomas Bachmann brings over twenty-five years of global experience in sales and marketing, in leading and transforming complex businesses, as well as in strategy and business development to his new role as Bruker BioSpin Group President, including experience as a CEO of two publicly traded companies. From 2005 until 2012, Mr. Bachmann served as CEO of Tecan Group, where he increased operational effectiveness, expanded into new businesses, developed emerging markets, created a solid organization, established regulatory competence and compliance, grew profitability and built a strong balance sheet. From 2002 until 2004, he was CEO of the Arbonia-Forster Group's Steel Systems Business, a global provider of building supplies. From 1985 until 2002, Mr. Bachmann served in various roles as global Sales and Marketing Director, Business Unit Director and Senior Vice President of Corporate Development at Rieter Holding, a global provider of textile machinery and plants, as well as an automotive supplier of acoustic- and thermal insulation systems. Mr. Bachmann holds a B.Sc. in Mechanical Engineering and an Executive MBA from IMD Business School in Switzerland.
Tiny Kidneys: Building Better Models to Test DrugsNews
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.READ MORE
Radioprotective Drugs Assessed Using Human Gut Organ-on-a-ChipNews
Researchers have published a study using an organ-on-a-chip (Organ Chip) model of the human gut that reveals the intestinal blood vessel cells may play an important part in radiation-induced intestinal injury, and it confirms that a potential radioprotective drug, dimethyloxaloylglycine (DMOG), suppresses the intestine’s responses to radiation injury.READ MORE
Putting Statistics into Forensic Firearms IdentificationNews
During criminal investigations, firearms examiners can offer an expert opinion as to whether two bullets or cartridge cases match, However, they cannot express the strength of the evidence numerically, the way a DNA expert can when testifying about genetic evidence. Now, a team has developed a statistical approach for ballistic comparisons that may enable numerical testimony.READ MORE